A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

• PF-06835919 25 mg (Drug): PF-06835919 in 25 mg oral tablet will be administered on Day 1

Primary outcomes

• Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06835919 [Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 ,72, 96 ,120 hours post dose on Day 1.]: AUCinf was defined as area under the plasma concentration time curve from time 0 extrapolated to infinite time.
• Maximum Plasma Concentration (Cmax) of PF-06835919 [Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 ,72, 96 ,120 hours post dose on Day 1.]: Cmax was defined as maximum plasma concentration of PF-06835919 and observed directly from data.
• Unbound Area Under The Plasma Concentration-Time Curve From Time 0 Extrapolated To Infinite Time (AUCinf,u) of PF-06835919 [Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 ,72, 96 ,120 hours post dose on Day 1.]: AUCinf,u was defined as unbound area under the plasma concentration time curve from time 0 extrapolated to infinite time.
• Unbound Maximum Plasma Concentration (Cmax,u) of PF-06835919 [Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 ,72, 96 ,120 hours post dose on Day 1.]: Cmax,u was defined as unbound maximum plasma concentration.
• Fraction of Drug Unbound (fu) of PF-06835919 [Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48 ,72, 96 ,120 hours post dose on Day 1.]: The fraction of PF-06835919 unbound in plasma (fu) was determined at approximately the expected Tmax in each participant.

Secondary outcomes

• Number of Participants Reporting Treatment-emergent Adverse Events (AEs) [Baseline (Day 1) up to follow-up (Day 31)]: An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AE (TEAE) was defined as an AE with onset date occurring during the on-treatment period. AEs included all SAEs and non-SAEs.
• Number of Participants With Clinically Significant Change (Chg) From Baseline in Laboratory Tests [Baseline (Day 1) up to Day 6]: To determine if there were any clinically significant laboratory abnormalities, hematology (hemoglobin, hematocrit, erythrocytes, mean corpuscular hemoglobin, mean corpuscular volume, platelet count, lymphocytes, neutrophils, activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio), clinical chemistry (bilirubin, direct and indirect bilirubin, gamma glutamyl transferase, albumin, urea nitrogen, glucose) and urinalysis (glucose, protein, hemoglobin, urobilinogen, nitrite) tests were assessed. Each parameter was evaluated against commonly used and widely accepted criteria.
• Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECGs) [Baseline (Day 1) up to Day 6]: ECG endpoints (PR interval, QRS interval, QT interval and QTcF) meeting the criteria of potential clinical concern were summarized by treatment using categories as defined: 1. PR max. ≥300ms, %Chg ≥25/50%; 3. QRS max. ≥140ms，%Chg ≥50%; 3.maximum post-dose QTcF 450 - ≤480msec, 480 - ≤500msec and >500msec, 30<Chg≤60 and Chg>60.

Sex: All, ages: 18 Years to 70 Years, accepts healthy volunteers

Inclusion Criteria:

* Male and female participants between the ages of 18 (or the minimum country specific age of consent if >18) and 70 years, inclusive, at the Screening visit:
* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
* Body mass index (BMI) of 17.5 to 35.4 kg/m2; and a total body weight >50 kg (110 lb).
* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion Criteria:

* Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).

(Participants who have undergone cholecystectomy and/or appendectomy are eligible for this study as long as the surgery occurred more than 6 months prior to Screening)..

* At Screening, participants with a positive result for human immunodeficiency virus (HIV) antibodies, as assessed by sponsor identified central laboratory, with a single repeat permitted to assess eligibility, if needed.
* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behaviour or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
* Use of prior/concomitant therapies.
* Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer).
* Participants with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a study involving PF 06835919.
* A positive urine drug test, for illicit drugs, and/or a positive breath alcohol test at Screening. However, participants who have been medially prescribed opiates/opiods or benzodiazepines and report the use of these drugs to the investigator at the screening visit will be allowed to participate.
* Male participants with partners who are currently pregnant.
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing and until the follow-up contact.
* History of sensitivity to heparin or heparin induced thrombocytopenia, only if heparin is used to flush intravenous catheters used during serial blood collections.
* Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of the protocol.
* Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.

Participant flow

Outcome results

• Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06835919 (Primary), Geometric mean, nanogram*hour per milliliter (ng*hr/mL): Without Hepatic Impairment 14090 +/- 29; Mild Hepatic Impairment 13090 +/- 36; Moderate Hepatic Impairment 18930 +/- 34; Severe Hepatic Impairment 19630 +/- 28
• Maximum Plasma Concentration (Cmax) of PF-06835919 (Primary), Geometric mean, ng/mL: Without Hepatic Impairment 1310 +/- 17; Mild Hepatic Impairment 1143 +/- 47; Moderate Hepatic Impairment 1340 +/- 28; Severe Hepatic Impairment 1098 +/- 31
• Unbound Area Under The Plasma Concentration-Time Curve From Time 0 Extrapolated To Infinite Time (AUCinf,u) of PF-06835919 (Primary), Geometric mean, ng*hr/mL: Without Hepatic Impairment 612.6 +/- 29; Mild Hepatic Impairment 746.2 +/- 22; Moderate Hepatic Impairment 1093 +/- 43; Severe Hepatic Impairment 1199 +/- 34
• Unbound Maximum Plasma Concentration (Cmax,u) of PF-06835919 (Primary), Geometric mean, ng/mL: Without Hepatic Impairment 56.93 +/- 18; Mild Hepatic Impairment 65.16 +/- 32; Moderate Hepatic Impairment 77.45 +/- 26; Severe Hepatic Impairment 67.10 +/- 30
• Fraction of Drug Unbound (fu) of PF-06835919 (Primary), Geometric mean, ratio: Without Hepatic Impairment 0.04345 +/- 5; Mild Hepatic Impairment 0.05704 +/- 21; Moderate Hepatic Impairment 0.05780 +/- 18; Severe Hepatic Impairment 0.06111 +/- 14
• Number of Participants Reporting Treatment-emergent Adverse Events (AEs) (Secondary), Count of participants, Participants: Without Hepatic Impairment 0; Mild Hepatic Impairment 0; Moderate Hepatic Impairment 1; Severe Hepatic Impairment 1
• Number of Participants With Clinically Significant Change (Chg) From Baseline in Laboratory Tests (Secondary), Count of participants, Participants: Without Hepatic Impairment 0; Mild Hepatic Impairment 0; Moderate Hepatic Impairment 1; Severe Hepatic Impairment 0
• Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECGs) (Secondary), Count of participants, Participants: Without Hepatic Impairment 0; Mild Hepatic Impairment 0; Moderate Hepatic Impairment 0; Severe Hepatic Impairment 0

Adverse events

Time frame: Baseline (Day 1) up to follow-up (Day 31)

Other adverse events by term

• Study Protocol (PDF, 2020-02-18)
• Statistical Analysis Plan (PDF, 2021-09-03)

• Pfizer CT.gov Call Center, Study director, Pfizer

NIH grants: 2019